Crystal form and amorphous form of carebastine p-toluenesulfonate

MYPI2025001580A0Undetermined Publication Date: 2024-07-03CHENGDU SHIBEIKANG BIOLOGICAL MEDICINE TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025001580
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-01-03
Filing Date
2023-04-14
Publication Date
2024-07-03

AI Technical Summary

Technical Problem

Caristin has shortcomings such as being photo-instable, difficult to purify, difficult to scale up and synthesize, and difficult to make into a drug. As a result, there is currently no marketed drug, and there is a lack of detailed reports on its salts, especially the crystalline form of Caristin p-toluenesulfonate. Type and amorphous forms have not been reported.

Method used

Provides a crystalline and amorphous form of carristin p-toluenesulfonate, which has high stability, good hygroscopicity, high bioavailability, and is easy to purify, suitable for scale-up production, and provides corresponding preparation methods, including in organic Heat and stir in the solvent to dissolve and react to form a salt, cool down to precipitate a solid, and filter it with suction to obtain crude carristine p-toluenesulfonate.

Benefits of technology

It has achieved high purity and stability of carristin p-toluenesulfonate, simplified the production process, improved pharmacokinetic properties, higher blood concentration, fast onset of action, longer half-life, and has the ability to be used in acute Therapeutic potential for allergic diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025001580_DRAWING_001
    Figure PI2025001580_DRAWING_001
  • Figure PI2025001580_DRAWING_002
    Figure PI2025001580_DRAWING_002
  • Figure PI2025001580_DRAWING_003
    Figure PI2025001580_DRAWING_003
Patent Text Reader

Abstract

Provided are a crystal form and amorphous form of carebastine p-toluenesulfonate, and a preparation method therefor, relating to the field of medicinal chemistry, for use in solving the problems in the prior art that carebastine is unstable, not easy to scale up for synthesis, and difficult to make into a drug and the like. The crystal form and amorphous form of carebastine p-toluenesulfonate have the characteristics of high purity, high stability, high bioavailability, easy scale-up synthesis, and industrial production and the like, and have excellent hygroscopicity for easy storage.
Need to check novelty before this filing date? Find Prior Art

Description

Crystalline and amorphous forms of Carusten p-toluenesulfonate

[0001] This application claims priority to the invention patent entitled “Crystalline and Amorphous Forms of Carusin p-Toluenesulfonate” filed on January 3, 2023, with patent number CN202310000722.6, which is hereby expressly incorporated herein by reference. Technical Field

[0002] The present invention relates to the technical field of pharmaceutical chemistry, and in particular to a crystalline form and an amorphous form of carristenol p-toluenesulfonate, as well as uses and preparation methods thereof. Background Art

[0003] Carebastine is the active metabolite of the second-generation histamine H1 receptor antagonist ebastine. It does not enter the central nervous system, has no adverse central nervous system effects and anticholinergic effects, and can avoid the first-pass effect of ebastine in the liver. It takes effect quickly and can be used to treat allergic diseases: urticaria, allergic rhinitis, eczema, dermatitis, prurigo, pruritus, etc. It is especially suitable for the emergency treatment of acute allergic diseases such as acute hives and asthma.

[0004] However, Carustin suffers from drawbacks such as photoinstability, difficulty in purification, difficulty in scale-up synthesis, and difficulty in drug development. Consequently, there are currently no marketed Carustin drugs. Furthermore, there are no detailed reports on Carustin salts, particularly Carustin p-toluenesulfonate and its crystalline and amorphous forms. The present invention aims to provide a crystalline and amorphous form of Carustin p-toluenesulfonate to overcome these drawbacks of the existing technology and provide a reliable clinical option. Summary of the Invention

[0005] To address at least one of the technical problems of the prior art, the present invention provides a crystalline form and an amorphous form of Carusten p-toluenesulfonate. The crystalline form and amorphous form of Carusten p-toluenesulfonate of the present invention have high stability, good hygroscopicity, high bioavailability, are easy to purify, are suitable for scale-up production, and are advantageous for drug development.

[0006] In one aspect, the present invention provides a crystalline form of carrestin p-toluenesulfonate having a structure as shown in formula (1). .

[0007] Using Cu-Kα radiation, the X-ray powder diffraction pattern of the crystalline form has diffraction peaks at the following 2θ values: 4.26±0.2°, 6.43±0.2°, 14.49±0.2°, 15.11±0.2°, and 18.95±0.2°.

[0008] Furthermore, the X-ray powder diffraction pattern of the above-mentioned crystal form has diffraction peaks at the following 2θ values: 4.26±0.2°, 6.43±0.2°, 14.49±0.2°, 15.11±0.2°, 18.95±0.2°, and optionally 19.12±0.2°.

[0009] Furthermore, the X-ray powder diffraction pattern of the above-mentioned crystal form has diffraction peaks at the following 2θ values: 4.26±0.2°, 6.43±0.2°, 13.10±0.2°, 14.49±0.2°, 15.11±0.2°, 15.77±0.2°, and 18.95±0.2°.

[0010] Preferably, the X-ray powder diffraction pattern of the above-mentioned crystal form has diffraction peaks at the following 2θ values: 4.26±0.2°, 6.43±0.2°, 13.10±0.2°, 14.49±0.2°, 15.11±0.2°, 15.77±0.2°, 18.95±0.2°, and 19.12±0.2°.

[0011] Furthermore, the X-ray powder diffraction pattern of the above-mentioned crystal form has diffraction peaks at the following 2θ values: 4.26±0.2°, 6.43±0.2°, 13.10±0.2°, 14.49±0.2°, 15.11±0.2°, 15.77±0.2°, 18.95±0.2°, 19.59±0.2°, 23.49±0.2°, and 24.97±0.2°.

[0012] Preferably, the X-ray powder diffraction pattern of the above-mentioned crystal form has diffraction peaks at the following 2θ values: 4.26±0.2°, 6.43±0.2°, 13.10±0.2°, 14.49±0.2°, 15.11±0.2°, 15.77±0.2°, 18.95±0.2°, 19.12±0.2°, 19.59±0.2°, 23.49±0.2°, and 24.97±0.2°.

[0013] Furthermore, the X-ray powder diffraction pattern of the above-mentioned crystalline form has diffraction peaks at the following 2θ values: 4.26±0.2°, 6.43±0.2°, 13.10±0.2°, 13.97±0.2°, 14.16±0.2°, 14.49±0.2°, 15.11±0.2°, 15.43±0.2°, 15.77±0.2°, 18.95± 0.2°, 19.12±0.2°, 19.34±0.2°, 19.59±0.2°, 23.49±0.2°, 23.87±0.2°, 24.11±0.2°, 24.97±0.2°, 25.15±0.2°, 25.73±0.2°, 26.10±0.2°, 28.98±0.2°, 29.28±0.2°.

[0014] Preferably, the X-ray powder diffraction pattern of the above-mentioned crystalline form has diffraction peaks at the following 2θ values: 4.26±0.2°, 6.43±0.2°, 13.10±0.2°, 13.97±0.2°, 14.16±0.2°, 14.49±0.2°, 15.11±0.2°, 15.43±0.2°, 15.61±0.2°, 15.77±0.2°, 18 .95±0.2°, 19.12±0.2°, 19.34±0.2°, 19.59±0.2°, 23.49±0.2°, 23.87±0.2°, 24.11±0.2°, 24.97±0.2°, 25.15±0.2°, 25.73±0.2°, 26.10±0.2°, 28.98±0.2°, 29.28±0.2°.

[0015] Furthermore, the X-ray powder diffraction pattern of the above-mentioned crystalline form has diffraction peaks at the following 2θ values: 4.26±0.2°, 6.43±0.2°, 10.77±0.2°, 12.41±0.2°, 12.56±0.2°, 12.78±0.2°, 13.10±0.2°, 13.97±0.2°, 14.16±0.2°, 14.49±0.2°, 15.11±0.2°, 15.43±0 .2°, 15.77±0.2°, 18.95±0.2°, 19.12±0.2°, 19.34±0.2°, 19.59±0.2°, 23.49±0.2°, 23.87±0.2°, 24.11±0.2°, 24.97±0.2°, 25.15±0.2°, 25.73±0.2°, 26.10±0.2°, 28.98±0.2°, 29.28±0.2°.

[0016] Preferably, the X-ray powder diffraction pattern of the above-mentioned crystalline form has diffraction peaks at the following 2θ values: 4.26±0.2°, 6.43±0.2°, 10.77±0.2°, 12.41±0.2°, 12.56±0.2°, 12.78±0.2°, 13.10±0.2°, 13.97±0.2°, 14.16±0.2°, 14.49±0.2°, 15.11±0.2°, 15.43±0.2°, 15 .61±0.2°, 15.77±0.2°, 18.95±0.2°, 19.12±0.2°, 19.34±0.2°, 19.59±0.2°, 23.49±0.2°, 23.87±0.2°, 24.11±0.2°, 24.97±0.2°, 25.15±0.2°, 25.73±0.2°, 26.10±0.2°, 28.98±0.2°, 29.28±0.2°.

[0017] Furthermore, the X-ray powder diffraction pattern of the above-mentioned crystal form has characteristic peaks and their relative intensities at the following positions at a diffraction angle 2θ: .

[0018] Preferably, the X-ray powder diffraction pattern of the above-mentioned crystal form has characteristic peaks and their relative intensities at the following positions at a diffraction angle 2θ: .

[0019] Furthermore, the X-ray powder diffraction pattern of the above-mentioned crystal form has characteristic peaks and their relative intensities at the following positions at a diffraction angle 2θ: .

[0020] Preferably, the X-ray powder diffraction pattern of the above-mentioned crystal form has characteristic peaks and their relative intensities at the following positions at a diffraction angle 2θ: .

[0021] Furthermore, the above-mentioned crystalline form has an X-ray powder diffraction pattern substantially as shown in FIG1 .

[0022] It is worth noting that in the X-ray powder diffraction pattern of the above-mentioned crystal form, due to differences in detection conditions, such as the degree of powder grinding, there may be unclear peaks at the following 2θ values, or they may be swallowed up by large peaks and appear flat or slightly bulging, such as 15.61±0.2, 19.12±0.2°, and 25.15±0.2°. It should be understood that minor differences in these peak positions and peak morphologies are within the scope of the present invention.

[0023] Furthermore, the differential scanning calorimetry spectrum of the above-mentioned crystal form has an endothermic peak at 171°C±5°C.

[0024] Preferably, the differential scanning calorimetry spectrum of the above-mentioned crystal form has an endothermic peak at 171.51°C±3°C.

[0025] Further preferably, the differential scanning calorimetry spectrum of the above-mentioned crystal form has an endothermic peak at 171.51°C±1.0°C.

[0026] Furthermore, the above-mentioned crystal form has a differential scanning calorimetry curve substantially as shown in FIG2 .

[0027] Furthermore, the above-mentioned crystal form has a thermogravimetric analysis spectrum substantially as shown in FIG3 .

[0028] On the other hand, the present invention also provides an amorphous form of carrestin p-toluenesulfonate having a structure as shown in formula (1). .

[0029] Furthermore, the amorphous phase has an X-ray powder diffraction pattern showing diffuse peaks using Cu-Kα radiation; preferably, the amorphous phase has an X-ray powder diffraction pattern substantially as shown in FIG5 .

[0030] In a third aspect, the present invention provides a method for preparing any one of the above-mentioned crystalline forms or any one of the amorphous forms, comprising the following salt-forming step: heating and stirring an appropriate amount of 2-(4-(4-(diphenylmethoxy)piperidin-1-yl)butyryl)phenyl)-2-methylpropionic acid and p-toluenesulfonic acid in an organic solvent to dissolve and react to form a salt, cooling after the reaction is completed, precipitating a solid, and filtering to obtain a crude product of carristin p-toluenesulfonate.

[0031] Furthermore, the organic solvent used in the above-mentioned salt formation step includes, but is not limited to, alcohols, esters, ethers, ketones, aromatic hydrocarbons, diol derivatives, pyrrolidones, tetrahydrofurans, amides or others.

[0032] Furthermore, the above-mentioned alcohols include C1~C6 straight-chain or branched saturated alkyl alcohols, preferably methanol, ethanol, propanol or isopropanol; esters include lower alkyl esters, preferably ethyl acetate, propyl acetate or isopropyl acetate; ethers include lower alkyl ethers, preferably tert-methyl ether or ethyl ether; ketones include lower alkanones, preferably acetone and butanone; aromatic hydrocarbons include benzene, toluene, xylene or trimethylbenzene, preferably toluene; glycol derivatives include ethylene glycol monomethyl ether, ethylene glycol monoethyl ether or ethylene glycol monobutyl ether, etc., preferably ethylene glycol monomethyl ether; pyrrolidones include N-methylpyrrolidone or N-ethylpyrrolidone; tetrahydrofurans include tetrahydrofuran or 2-methyltetrahydrofuran; amides include N,N-dimethylformamide or N,N-dimethylacetamide; other types include dioxane, acetonitrile, dimethyl sulfoxide or mixtures of the above organic solvents with water.

[0033] Further preferably, the above-mentioned organic solvent includes methanol, ethanol, isopropanol, acetone, butanone, acetonitrile, ethyl acetate, isopropyl acetate, toluene, tetrahydrofuran, dioxane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, N-methylpyrrolidone, methyl tert-ether, diethyl ether, dimethyl sulfoxide or a mixture of the above organic solvents and water.

[0034] Furthermore, the organic solvent comprises ethanol, butanone, acetonitrile or isopropyl acetate.

[0035] Furthermore, the reaction temperature of the above-mentioned salt formation step is 40-100°C; preferably 60-90°C.

[0036] Furthermore, the solidification temperature of the above-mentioned salt formation step is -20~30°C; preferably -5~20°C.

[0037] Furthermore, the present invention provides a method for preparing the above-mentioned crystal form, comprising the following steps: taking crude carristin p-toluenesulfonate, adding a solvent, heating and stirring, cooling and crystallizing, filtering, and drying to obtain carristin p-toluenesulfonate crystals.

[0038] Furthermore, the solvent used in the above-mentioned crystal preparation method includes one or more of water, alcohols, esters, ethers, ketones, aromatic hydrocarbons, diol derivatives, pyrrolidones, tetrahydrofurans, amides, and other organic solvents.

[0039] Furthermore, the above-mentioned alcohols include C1~C6 straight-chain or branched saturated alkyl alcohols, preferably methanol, ethanol, propanol or isopropanol; esters include lower alkyl esters, preferably ethyl acetate, propyl acetate or isopropyl acetate; ethers include lower alkyl ethers, preferably methyl tert-ether or ethyl ether; ketones include lower alkanones, preferably acetone and butanone; aromatic hydrocarbons include benzene, toluene, xylene or trimethylbenzene, preferably toluene; glycol derivatives include ethylene glycol monomethyl ether, ethylene glycol monoethyl ether or ethylene glycol monobutyl ether, preferably ethylene glycol monomethyl ether; pyrrolidones include N-methylpyrrolidone or N-ethylpyrrolidone; tetrahydrofurans include tetrahydrofuran or 2-methyltetrahydrofuran; amides include N,N-dimethylformamide or N,N-dimethylacetamide; other organic solvents include dioxane, acetonitrile or dimethyl sulfoxide.

[0040] Further preferably, the solvent used in the above-mentioned crystal preparation method includes one or more of water, methanol, ethanol, isopropanol, ethyl acetate, isopropyl acetate, methyl tert-ether, acetone, butanone, toluene, ethylene glycol monomethyl ether, N-methylpyrrolidone, N-ethylpyrrolidone, tetrahydrofuran, N,N-dimethylformamide, N,N-dimethylacetamide, dioxane, acetonitrile, and dimethyl sulfoxide.

[0041] More preferably, the solvent used in the above-mentioned crystal preparation method includes one or two of water, methanol, ethanol, isopropanol, ethyl acetate, isopropyl acetate, methyl tert-ether, acetone, butanone, toluene, N-methylpyrrolidone, N-ethylpyrrolidone, tetrahydrofuran, N,N-dimethylformamide, N,N-dimethylacetamide, dioxane, acetonitrile, and dimethyl sulfoxide.

[0042] In particular, when a composite solvent is used, a mixture of the above-mentioned organic solvent and water is preferred.

[0043] Furthermore, the crystallization temperature in the above-mentioned crystal form preparation method is 30~100°C; preferably 50~90°C.

[0044] Furthermore, the crystallization temperature of the above-mentioned crystal preparation method is -20~35°C; preferably -5~25°C; more preferably 0~20°C.

[0045] Furthermore, the above-mentioned amorphous preparation method includes the following steps: taking the crude product of carristin p-toluenesulfonate and adding it to a solvent, heating and refluxing, filtering after the solid is completely dissolved, and spray drying or freeze-drying the filtrate to obtain a white solid.

[0046] Furthermore, the solvent used in the above-mentioned amorphous preparation method includes one or more of water, alcohols, esters, ethers, ketones, aromatic hydrocarbons, diol derivatives, pyrrolidones, tetrahydrofurans, amides, and other organic solvents.

[0047] Furthermore, the above-mentioned alcohols include C1~C6 straight-chain or branched saturated alkyl alcohols, preferably methanol, ethanol, propanol or isopropanol; esters include lower alkyl esters, preferably ethyl acetate, propyl acetate or isopropyl acetate; ethers include lower alkyl ethers, preferably methyl tert-ether or ethyl ether; ketones include lower alkanones, preferably acetone and butanone; aromatic hydrocarbons include benzene, toluene, xylene or trimethylbenzene, preferably toluene; glycol derivatives include ethylene glycol monomethyl ether, ethylene glycol monoethyl ether or ethylene glycol monobutyl ether, preferably ethylene glycol monomethyl ether; pyrrolidones include N-methylpyrrolidone or N-ethylpyrrolidone; tetrahydrofurans include tetrahydrofuran or 2-methyltetrahydrofuran; amides include N,N-dimethylformamide or N,N-dimethylacetamide; other organic solvents include dioxane, acetonitrile or dimethyl sulfoxide.

[0048] Further preferably, the solvent used in the above-mentioned amorphous preparation method includes one or more of water, methanol, ethanol, isopropanol, ethyl acetate, isopropyl acetate, methyl tert-ether, acetone, butanone, toluene, ethylene glycol monomethyl ether, N-methylpyrrolidone, N-ethylpyrrolidone, tetrahydrofuran, N,N-dimethylformamide, N,N-dimethylacetamide, dioxane, acetonitrile, and dimethyl sulfoxide.

[0049] More preferably, the solvent used in the above-mentioned amorphous preparation method includes one or two of water, methanol, ethanol, isopropanol, ethyl acetate, isopropyl acetate, methyl tert-ether, acetone, butanone, toluene, N-methylpyrrolidone, N-ethylpyrrolidone, tetrahydrofuran, N,N-dimethylformamide, N,N-dimethylacetamide, dioxane, acetonitrile, and dimethyl sulfoxide.

[0050] In particular, when a composite solvent is used, a mixture of the above-mentioned organic solvent and water is preferred.

[0051] Furthermore, the reflux temperature in the above amorphous preparation method is 30-100°C, preferably 50-90°C.

[0052] In a fourth aspect, the present invention further provides a pharmaceutical composition comprising any one of the above-mentioned crystalline or amorphous forms of Carustin p-toluenesulfonate, characterized in that the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

[0053] The above-mentioned "pharmaceutically acceptable carrier" refers to a diluent, adjuvant, excipient or vehicle that is administered together with the active ingredient and is suitable for contact with the tissues of humans and / or other animals within the scope of reasonable medical judgment without excessive toxicity, irritation, allergic reaction or other problems or complications corresponding to a reasonable benefit / risk ratio.

[0054] In a fifth aspect, the present invention further provides use of any of the aforementioned crystalline or amorphous forms of the p-toluenesulfonate of Carustin in the preparation of drugs that are histamine H1 receptor antagonists.

[0055] Furthermore, the above-mentioned use includes use in preparing drugs for treating and / or preventing allergic diseases.

[0056] Furthermore, the above-mentioned allergic diseases also include acute allergic diseases.

[0057] Furthermore, the above-mentioned allergic disease is selected from urticaria, allergic rhinitis, eczema, dermatitis or pruritus; preferably, the above-mentioned acute allergic disease is selected from acute urticaria or acute allergic rhinitis.

[0058] Note: In the absence of contrary evidence or special explanation, the compound represented by formula (1) of the present invention indicates that the mass molar ratio of carristol-pyrrole to p-toluenesulfonic acid is 1:1; the mass molar ratio of the corresponding crystalline form and amorphous form is also 1:1.

[0059] The solvent used in the method for preparing the crystalline form and the amorphous form of the present invention includes the term "the above-mentioned organic solvent" in "a mixture of the above-mentioned organic solvent and water", which includes but is not limited to all the organic solvents listed in the present invention.

[0060] The term "crude product" in the present invention refers to a drug having a purity of no higher than 99%, preferably no higher than 98.5%. Beneficial effects

[0061] Compared with the prior art, the present invention has the following beneficial effects:

[0062] The crystalline and amorphous forms of the p-toluenesulfonate salt of Carusten in the present invention (1) have a good pharmaceutical solid form, are non-hygroscopic or slightly hygroscopic, have high purity and stability, and are easy to transport and store; (2) have a simple production process, are made of cheap and readily available materials, are easy to scale up, have a short production cycle, and are energy-saving and environmentally friendly; (3) have better pharmacokinetic properties, higher blood drug concentrations, faster onset time, and longer half-life, and have the potential to be used in the treatment of acute allergic diseases such as acute urticaria, with stronger and more lasting efficacy and high safety. BRIEF DESCRIPTION OF THE DRAWINGS

[0063] FIG1 is an X-ray powder diffraction (XRPD) pattern of the crystalline form of Carusten p-toluenesulfonate;

[0064] FIG2 is a differential scanning calorimetry (DSC) diagram of the crystalline form of Carustin p-toluenesulfonate;

[0065] FIG3 is a thermogravimetric analysis (TGA) diagram of the crystal form of Carustin p-toluenesulfonate;

[0066] FIG4 is an XRPD stack of the crystalline form of Carustin p-toluenesulfonate of Examples 2 to 6;

[0067] FIG5 is an X-ray powder diffraction (XRPD) pattern of amorphous form of Carusten p-toluenesulfonate. Modes for Carrying Out the Invention

[0068] The present invention will be further described in detail below in conjunction with embodiments and test examples. The embodiments and test examples of the present invention are only used to illustrate the technical solutions of the present invention and are not intended to limit the present invention. Any equivalent substitutions in the art made in accordance with the contents disclosed in the present invention shall fall within the scope of protection of the present invention.

[0069] The structure of the compound was determined by NMR ( 1 H NMR) or liquid chromatography-mass spectrometry (LC-MS).

[0070] The liquid chromatography-mass spectrometer (LC-MS) was Agilent G6120B (used with Agilent 1260 liquid chromatography); the nuclear magnetic resonance instrument ( 1 H NMR) was performed on a Bruker AVANCE~400 or Bruker AVANCE~800, and nuclear magnetic resonance ( 1H NMR) shifts (δ) are given in parts per million (ppm) using CDCl3 as the solvent and tetramethylsilane (TMS) as the internal standard. Chemical shifts are expressed in 10 ~6 The units are given in ppm.

[0071] The term "room temperature" in the present invention refers to a temperature between 10 and 30°C.

[0072] The ebastine (Comparative Example 1) used in the following examples and test examples is in free form, commercially available, and has a purity of more than 98%; the carristine (Comparative Example 2) is in free form, commercially available, and has a purity of more than 99%.

[0073] Example 1: Preparation of crude 2-(4-(4-(4-(diphenylmethoxy)piperidin-1-yl)butyryl)phenyl)-2-methylpropanoic acid p-toluenesulfonate (Carustin p-toluenesulfonate)

[0074]

[0075] The synthetic route is as follows:

[0076] 2-(4-(4-(4-(diphenylmethoxy)piperidin-1-yl)butanoyl)phenyl)-2-methylpropionic acid (Carustine) (500 g, 0.1 mol) and 1 L of isopropanol were added to a three-necked flask and heated to 60-90°C. p-Toluenesulfonic acid (172 g, 1 mol) was added and stirred. The temperature was lowered to precipitate a white solid, which was filtered and dried to obtain 571 g of Carustine p-toluenesulfonate with a yield of 85% and a purity of 98.05%.

[0077] ESI-MS: m / z = 500.3(M+H) + .

[0078] 1 H NMR (600 MHz, CDCl3) δ: 10.01 (s, 1H), 7.80~7.83 (d, 2H), 7.74~7.76 (d, 2H), 7.43~7.46 (d, 2H), 7.27~7.37 (m, 10H), 7.13~7.15 (d, 2H), 5.44 (s, 1H), 3.83~3.85 (m, 1H), 3.53~3.55 (m, 2H), 3.10~3.17 (m, 4H), 3.00~3.05(m, 2H), 2.32 (s, 3H), 2.21~2.29 (m, 2H), 2.09~2.19 (m, 2H), 2.01~2.08 (m, 2H), 1.58 (s, 6H).

[0079] Example 2: Preparation of crystal form of Carustin p-toluenesulfonate

[0080]

[0081] Add 1.5 kg of ethanol and 100 g of crude carristin p-toluenesulfonate at room temperature, stir and heat to 60-80°C, keep stirring for 0.5-1.2 h; cool to 5-20°C and crystallize for 0.5-1.5 h; filter, wash the filter cake with ethanol, drain and dry to obtain 83 g of crystalline carristin p-toluenesulfonate with a yield of 83% and a purity of 99.42%.

[0082] ESI-MS: m / z = 500.3(M+H) +.

[0083] 1 H NMR (600 MHz, CDCl3) δ: 10.01 (s, 1H), 7.80~7.83 (d, 2H), 7.74~7.76 (d, 2H), 7.43~7.46 (d, 2H), 7.27~7.37 (m, 10H), 7.13~7.15 (d, 2H), 5.44 (s, 1H), 3.83~3.85 (m, 1H), 3.53~3.55 (m, 2H), 3.10~3.17 (m, 4H), 3.00~3.05(m, 2H), 2.32 (s, 3H), 2.21~2.29 (m, 2H), 2.09~2.19 (m, 2H), 2.01~2.08 (m, 2H), 1.58 (s, 6H).

[0084] The X-ray powder diffraction, differential scanning calorimetry, and thermogravimetric analysis results of the p-toluenesulfonate crystalline form of Carusten in this example are shown in Figures 1 to 3 .

[0085] Example 3: Preparation of Crystalline Form of Carustin p-Toluenesulfonate

[0086] At room temperature, add 500 mg of butanone and 50 mg of crude carristin p-toluenesulfonate. Stir and raise the temperature to 70-80°C, maintaining stirring for 0.2-1.0 h. Cool to 0-15°C to allow crystallization for 0.2-1.2 h. Filter, wash the filter cake with butanone, drain, and dry to obtain 45 mg of crystalline carristin p-toluenesulfonate, with a yield of 90% and a purity of 99.76%. Mass spectrometry, nuclear magnetic resonance, and X-ray powder diffraction were the same as in Example 2.

[0087] Example 4: Preparation of Crystalline Form of Carustin p-Toluenesulfonate

[0088] At room temperature, add 2 g of methyl tert-ether and 100 mg of crude carristin p-toluenesulfonate. Stir and raise the temperature to 30-55°C, maintaining stirring for 0.2-1.0 h. Cool to 0-20°C to allow crystallization for 0.2-1.5 h. Filter, wash the filter cake with methyl tert-ether, drain, and dry to obtain 95 mg of crystalline carristin p-toluenesulfonate, with a yield of 95% and a purity of 99.56%. Mass spectrometry, nuclear magnetic resonance, and X-ray powder diffraction were the same as in Example 2.

[0089] Example 5: Preparation of Crystalline Form of Carustin p-Toluenesulfonate

[0090] At room temperature, add 100 mg of isopropyl alcohol, 10 mg of water, and 100 mg of crude carristin p-toluenesulfonate. Stir and raise the temperature to 70-80°C, maintaining stirring for 0.2-1.0 h. Cool to 0-20°C to allow crystallization for 0.2-1.5 h. Filter, wash the filter cake with isopropyl alcohol, drain, and dry to obtain 85 mg of crystalline carristin p-toluenesulfonate, with a yield of 85% and a purity of 99.86%. Mass spectrometry, nuclear magnetic resonance, and X-ray powder diffraction were the same as in Example 2.

[0091] Example 6: Preparation of Crystalline Form of Carustin p-Toluenesulfonate

[0092] At room temperature, add 16 kg of acetonitrile and 2 kg of crude carristin p-toluenesulfonate. Stir and raise the temperature to 60-80°C, maintaining stirring for 0.5-1.2 hours. Cool to 5-20°C to allow crystallization for 0.5-1.5 hours. Filter, wash the filter cake with acetonitrile, drain, and dry to obtain 1.8 kg of crystalline carristin p-toluenesulfonate, with a yield of 90% and a purity of 99.66%. Mass spectrometry, nuclear magnetic resonance, and X-ray powder diffraction were the same as in Example 2.

[0093] Example 7: Preparation of Crystalline Form of Carustin p-Toluenesulfonate

[0094] At room temperature, add 1-2.5 kg of methanol and 100 g of crude carristin p-toluenesulfonate. Stir and heat to 40-60°C, maintaining stirring for 0.5-1.2 h. Cool to 0-15°C to allow crystallization for 0.5-1.5 h. Filter, wash the filter cake with methanol, drain, and dry to obtain 92 g of crystalline carristin p-toluenesulfonate, with a yield of 92% and a purity of 99.86%. Mass spectrometry, nuclear magnetic resonance, and X-ray powder diffraction were the same as in Example 2.

[0095] Example 8: Preparation of Crystalline Form of Carustin p-Toluenesulfonate

[0096] At room temperature, add 0.5-1.5 kg of tetrahydrofuran and 100 g of crude carristin p-toluenesulfonate. Stir and heat to 30-60°C, maintaining stirring for 0.5-1.2 h. Cool to 0-20°C to allow crystallization for 0.5-1.5 h. Filter, wash the filter cake with tetrahydrofuran, drain, and dry to obtain 85 g of crystalline carristin p-toluenesulfonate, with a yield of 85% and a purity of 99.96%. Mass spectrometry, nuclear magnetic resonance, and X-ray powder diffraction were the same as in Example 2.

[0097] Example 9: Preparation of Crystalline Form of Carustin p-Toluenesulfonate

[0098] At room temperature, add 1.5-2.5 kg of dioxane and 100 g of crude carristin p-toluenesulfonate. Stir and heat to 50-80°C, maintaining stirring for 0.5-1.2 h. Cool to 0-20°C to allow crystallization for 0.5-1.5 h. Filter, wash the filter cake with dioxane, drain, and dry to obtain 89 g of crystalline carristin p-toluenesulfonate, with a yield of 89% and a purity of 99.66%. Mass spectrometry, nuclear magnetic resonance, and X-ray powder diffraction analyses were the same as in Example 2.

[0099] Example 10: Preparation of Crystalline Form of Carustin p-Toluenesulfonate

[0100] At room temperature, add 1.5-2.5 kg of toluene and 100 g of crude carristin p-toluenesulfonate. Stir and heat to 80-100°C, maintaining stirring for 0.2-1.5 hours. Cool to 0-20°C to allow crystallization for 0.2-1.5 hours. Filter, wash the filter cake with toluene, drain, and dry to obtain 92 g of crystalline carristin p-toluenesulfonate, with a yield of 92% and a purity of 99.76%. Mass spectrometry, nuclear magnetic resonance, and X-ray powder diffraction analyses were the same as in Example 2.

[0101] Example 11: Preparation of Crystalline Form of Carustin p-Toluenesulfonate

[0102] At room temperature, add 1.0-2.5 kg of water and 100 g of crude carristin p-toluenesulfonate. Stir and heat to 80-100°C, maintaining stirring for 0.2-1.5 hours. Cool to 0-20°C to allow crystallization for 0.2-1.5 hours. Filter, wash the filter cake with water, drain, and dry to obtain 95 g of crystalline carristin p-toluenesulfonate, with a yield of 95% and a purity of 99.66%. Mass spectrometry, nuclear magnetic resonance, and X-ray powder diffraction were the same as in Example 2.

[0103] Example 12: Preparation of Crystalline Form of Carustin p-Toluenesulfonate

[0104] At room temperature, add 0.5-2.5 kg of dimethyl sulfoxide, 0.1-0.5 kg of water, and 100 g of crude carristin p-toluenesulfonate. Stir and heat to 80-100°C, maintaining stirring for 0.2-1.5 hours. Cool to 0-20°C to allow crystallization for 0.2-1.5 hours. Filter, wash the filter cake with water, drain, and dry to obtain 95 g of crystalline carristin p-toluenesulfonate, with a yield of 95% and a purity of 99.86%. Mass spectrometry, nuclear magnetic resonance, and X-ray powder diffraction analyses were the same as in Example 2.

[0105] Example 13: Preparation of Crystalline Form of Carustin p-Toluenesulfonate

[0106] At room temperature, add 0.5-2.5 kg of acetonitrile, 0.1-0.5 kg of methanol, and 100 g of crude carristin p-toluenesulfonate. Stir and heat to 30-60°C, maintaining stirring for 0.2-1.5 hours. Cool to 0-20°C to allow crystallization for 0.2-1.5 hours. Filter, wash the filter cake with acetonitrile, drain, and dry to obtain 99 g of crystalline carristin p-toluenesulfonate, with a yield of 99% and a purity of 99.16%. Mass spectrometry, nuclear magnetic resonance, and X-ray powder diffraction were the same as in Example 2.

[0107] Comparison of the crystal structure confirmation data of the carristine p-toluenesulfonate salts of Examples 2 to 13 shows that they all belong to the same crystal form, wherein the overlapping X-ray powder diffraction patterns of the crystal forms of Examples 2 to 6 are shown in Figure 4; this demonstrates that the crystal form of the carristine p-toluenesulfonate salt of the present invention is highly reproducible, easy to prepare, and suitable for scale-up production.

[0108] Example X: Preparation of amorphous form of Carustin p-toluenesulfonate

[0109] Take 1 kg of crude carrestin p-toluenesulfonate and add it to 2-4 kg of water. Heat under reflux and, after the solid is completely dissolved, filter it. Spray dry or freeze-dry the filtrate to obtain a white solid. X-ray powder diffraction analysis reveals an amorphous solid (see Figure 5 for details).

[0110] ESI-MS: m / z = 500.3(M+H) +.

[0111] 1H NMR (600 MHz, CDCl3) δ: 10.01 (s, 1H), 7.80~7.83 (d, 2H), 7.74~7.76 (d, 2H), 7.43~7.46 (d, 2H), 7.27~7.37 (m, 10H), 7.13~7.15 (d, 2H), 5.44 (s, 1H), 3.83~3.85 (m, 1H), 3.53~3.55 (m, 2H), 3.10~3.17 (m, 4H), 3.00~3.05(m, 2H), 2.32 (s, 3H), 2.21~2.29 (m, 2H), 2.09~2.19 (m, 2H), 2.01~2.08 (m, 2H), 1.58 (s, 6H).

[0112] Test Example 1: Stability Study

[0113] 1. Test samples: Carustin (Comparative Example 2), the crystalline form of Carustin p-toluenesulfonate (Example 2), and the amorphous form of Carustin p-toluenesulfonate (Example X).

[0114] 2. Test method:

[0115] Three portions of each of the samples of Carustin (Comparative Example 2), the crystalline form of Carustin p-toluenesulfonate (Example 2), and the amorphous form of Carustin p-toluenesulfonate (Example X) were weighed and placed in weighing bottles. Each group of samples was placed under high temperature (60°C), high humidity (RH80%), and light (5000 Lux) conditions, and samples were taken for testing after 30 days.

[0116] Detection Method: Take an appropriate amount of each sample, accurately weigh it, dissolve it in acetonitrile, and quantitatively dilute it to a solution containing approximately 0.08 mg per 1 ml. Perform high-performance liquid chromatography using octadecylsilane bonded silica gel as the filler, a water-acetonitrile (1:1) mobile phase, a detection wavelength of 256 nm, a column temperature of 35°C, and an injection volume of 10 μl. Inject each sample solution into the liquid chromatograph, and record the chromatogram. Calculate the content of carrestin using the external standard method, and the impurity content by peak area normalization.

[0117] 3. Test results:

[0118] After 30 days of testing under the influence of high temperature, high humidity, and light, the content of Carusten (Comparative Example 2) decreased by over 1.0% under high temperature and high humidity conditions, and by over 10% under light conditions, with the maximum single impurity content exceeding 0.5%. In contrast, the content of the crystalline form (Example 2) and amorphous form (Example X) of Carusten p-toluenesulfonate of the present invention decreased by no more than 0.1% under these conditions, with the maximum single impurity content not exceeding 0.1%. This demonstrates that the crystalline and amorphous forms of Carusten p-toluenesulfonate of the present invention are stable and more suitable for pharmaceutical use.

[0119]

[0120] Test Example 2: Moisture absorption study

[0121] 1. Test samples: Carustin (Comparative Example 2), Carustin hydrochloride (Comparative Example 3), the crystalline form of Carustin p-toluenesulfonate (Example 2), and the amorphous form of Carustin p-toluenesulfonate (Example X). Carustin hydrochloride was prepared according to the description in US Patent No. 6340761B1 and had a purity of over 99%.

[0122] 2. Test method:

[0123] (1) Take a dry glass weighing bottle with a stopper (outer diameter of 50 mm, height of 15 mm) and place it in a suitable constant temperature desiccator at 25℃±1℃ (with ammonium chloride or ammonium sulfate saturated solution placed at the bottom) or an artificial climate box (set temperature of 25℃±1℃, relative humidity of 80%±2%) one day before the test, and accurately weigh the weight (m1) with the lid on.

[0124] (2) Take an appropriate amount of the test sample and spread it flat in the above-mentioned weighing bottle. The thickness of the test sample is generally about 1 mm. Accurately weigh the weight with the lid (m2);

[0125] (3) Open the weighing bottle and place it with the bottle cap under the above constant temperature and humidity conditions for 24 hours;

[0126] (4) Cover the weighing bottle and accurately weigh the weight (m3);

[0127] (5) Weight gain percentage = (m3-m2) / (m2-m1)×100%.

[0128] 3. Test results:

[0129] The hygroscopicity results are shown in the following table: The results show that the crystalline form of the p-toluenesulfonate of Carustine of the present invention (Example 2) has no or almost no hygroscopicity, and the amorphous form of the p-toluenesulfonate of Carustine (Example X) has slightly hygroscopicity, but the free base of Carustine (Comparative Example 2) and its hydrochloride (Comparative Example 3) are hygroscopic and extremely hygroscopic, respectively; this proves that the crystalline form and amorphous form of the p-toluenesulfonate of Carustine of the present invention have better hygroscopic characteristics and are significantly superior to the free base of Carustine or its hydrochloride form.

[0130]

[0131] The above results are defined according to the pharmacopoeia: "Hygroscopic" means that the weight gain due to moisture is less than 15% but not less than 2%; "Extremely hygroscopic" means that the weight gain due to moisture is not less than 15%; "No or almost no hygroscopic" means that the weight gain due to moisture is less than 0.2%; "Slightly hygroscopic" means that the weight gain due to moisture is less than 2% but not less than 0.2%.

[0132] Test Example 3: Pharmacokinetic Test

[0133] This test example investigated the bioavailability of the crystalline and amorphous forms of Carusten p-toluenesulfonate through pharmacokinetic studies.

[0134] 1. Test drugs: Ebastine (Comparative Example 1), Carustine (Comparative Example 2), the crystalline form of Carustine p-toluenesulfonate (Example 2), and the amorphous form of Carustine p-toluenesulfonate (Example X) were prepared into enteric-coated capsules.

[0135] 2. Test method:

[0136] (1) Experimental animals

[0137] Species: Beagle;

[0138] Level: Ordinary;

[0139] Number and sex of animals: 8, male;

[0140] Age: All children were 1 to 2 years old when grouped;

[0141] Body weight: The body weight ranged from 8.90 to 10.3 kg, with a mean of 10.0 kg.

[0142] (2) Dosage and method of administration

[0143] Dosage: Calculated as Carustenin, each group received an equimolar dose. Appropriate amounts of compound were weighed and filled into capsules. This means each capsule contained 2.23 mg of Carustenin per capsule.

[0144]

[0145] After each test substance was filled into capsules, a 2×4 crossover test was conducted according to the above table. Calculated from the start of administration, 7 days was the washout period, and each group was given the corresponding test substance in different test cycles.

[0146] All animals were fasted overnight (more than 12 h) before each administration and resumed feeding 4 h after administration. Water was freely available.

[0147] (3) Plasma sample collection

[0148] Blood was collected at 13 points, 0 h before administration, and 10 min, 20 min, 30 min, 45 min, 1 h, 2 h, 3 h, 5 h, 6 h, 8 h, 10 h, and 24 h after administration.

[0149] According to the set blood collection time point, about 2 mL of blood was collected from the forelimb vein and placed in an EDTA-K2 anticoagulant tube. The whole blood sample was placed at room temperature and centrifuged within 1.5 hours after collection at a centrifugal force of 3000 g and 4°C for 10 min.

[0150] (4) Biological sample analysis

[0151] The concentration of carrestenin in plasma was determined by liquid chromatography-mass spectrometry (HPLC-MS / MS).

[0152] (5) Data collection and processing

[0153] The pharmacokinetic parameters of each group were calculated using the non-compartmental model using WinNonlin software (version 8.3 and above).

[0154] 3. Test results:

[0155] The pharmacokinetic test results of Carlistin in the plasma of beagle dogs in each group are shown in the table below.

[0156]

[0157] From the results in the table above, it can be seen that compared with the compound in Comparative Example 1, the peak time (T max ) is significantly faster, C max The AUC was improved by about 65%, 46% and 0-t The half-life (T 1 / 2 ) have also been extended.

[0158] Compared with the free compound in Comparative Example 2, the crystalline form of Example 2 and the amorphous form of Example X max The AUC was improved by about 55%, 37% and 0-tThe half-life (T 1 / 2 ) are also extended, and T max Basically the same.

[0159] Example 2 Crystalline Form C max and AUC 0-t Slightly higher than Example X amorphous, T 1 / 2 Also slightly longer.

[0160] In summary, the pharmacokinetic parameters of the crystalline form of Example 2 and the amorphous form of Example X are significantly better than those of the compounds of Comparative Examples 1 and 2, indicating that the crystalline form and amorphous form of the p-toluenesulfonate salt of Carustin of the present invention can quickly enter the body and inhibit histamine H1 receptors, and have the potential to be used clinically for the treatment of patients with acute allergic diseases such as acute urticaria, and have stronger and more lasting efficacy and higher safety.

[0161] The above embodiment is only one of the preferred implementation methods of the present invention and should not be used to limit the scope of protection of the present invention. Any changes or modifications that have no substantive meaning made to the main design concept and spirit of the present invention, as long as the technical problems they solve are still consistent with the present invention, should be included in the scope of protection of the present invention.

Claims

1. The crystal form of the compound represented by formula (1), , characterized in that, Using Cu-Kα radiation, the X-ray powder diffraction pattern of the crystalline form has diffraction peaks at the following 2θ values: 4.26±0.2°, 6.43±0.2°, 14.49±0.2°, 15.11±0.2°, and 18.95±0.2°.

2. The crystal form according to claim 1, characterized in that The X-ray powder diffraction pattern of the crystalline form has diffraction peaks at the following 2θ values: 4.26±0.2°, 6.43±0.2°, 13.10±0.2°, 14.49±0.2°, 15.11±0.2°, 15.77±0.2°, 18.95±0.2°, and optionally 19.12±0.2°.

3. The crystal form according to any one of claims 1 to 2, characterized in that The X-ray powder diffraction pattern of the crystalline form has diffraction peaks at the following 2θ values: 4.26±0.2°, 6.43±0.2°, 13.10±0.2°, 14.49±0.2°, 15.11±0.2°, 15.77±0.2°, 18.95±0.2°, optionally 19.12±0.2°, 19.59±0.2°, 23.49±0.2°, 24.97±0.2°.

4. The crystal form according to any one of claims 1 to 2, characterized in that The X-ray powder diffraction pattern of the crystal form has characteristic peaks and their relative intensities at the following positions at a diffraction angle 2θ: 。 5. The crystal form according to any one of claims 1 to 4, characterized in that: The crystalline form has an X-ray powder diffraction pattern substantially as shown in FIG1 .

6. The crystal form according to any one of claims 1 to 5, characterized in that The differential scanning calorimetry spectrum of the crystal form has an endothermic peak at 171°C±5°C; preferably, the crystal form has a differential scanning calorimetry curve substantially as shown in FIG. 2 .

7. The crystal form according to any one of claims 1 to 6, characterized in that The crystal form has a thermogravimetric analysis spectrum substantially as shown in FIG3 .

8. An amorphous form of the compound represented by formula (1), , It is characterized in that Using Cu—Kα radiation, the X-ray powder diffraction pattern of the amorphous form shows diffuse peaks; preferably, the amorphous form has an X-ray powder diffraction pattern substantially as shown in FIG. 5 .

9. A method for preparing the crystalline form according to any one of claims 1 to 7 or the amorphous form according to claim 8, characterized in that: The preparation method comprises the following salt-forming step: heating and stirring an appropriate amount of 2-(4-(4-(4-(diphenylmethoxy)piperidin-1-yl)butyryl)phenyl)-2-methylpropionic acid and p-toluenesulfonic acid in an organic solvent to dissolve and react to form salts, cooling after the reaction is completed, precipitating a solid, and drying to obtain a crude product of Carusten p-toluenesulfonate; preferably, the preparation method of the crystalline form comprises the following steps: taking a crude product of Carusten p-toluenesulfonate, adding a solvent, heating and stirring, cooling and crystallizing, filtering, and drying to obtain Carusten p-toluenesulfonate crystals; or / and the preparation method of the amorphous form comprises the following steps: taking a crude product of Carusten p-toluenesulfonate and adding it to a solvent, heating and refluxing, filtering after the solid is completely dissolved, and spray drying or freeze-drying the filtrate to obtain a white solid.

10. A pharmaceutical composition comprising the crystalline form according to any one of claims 1 to 7 or the amorphous form according to claim 8, characterized in that: The pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

11. Use of the crystalline form according to any one of claims 1 to 7 or the amorphous form according to claim 8 in the preparation of a histamine H1 receptor antagonist drug; further, the use includes use in the preparation of a drug for treating and / or preventing an allergic disease; preferably, the allergic disease is an acute allergic disease; further preferably, the allergic disease is selected from urticaria, allergic rhinitis, eczema, dermatitis or pruritus; further preferably, the acute allergic disease is acute urticaria or acute allergic rhinitis.